Ozempic vs Wegovy: the same semaglutide, two different drugs

What is the difference between Ozempic and Wegovy?

The short version: they are the same drug wearing two different labels. Both Ozempic and Wegovy contain semaglutide, both are made by Novo Nordisk, and both are once-weekly injections that curb appetite and lower blood sugar through the same receptor. If you drew the same milligram dose from each pen, you would be injecting the identical molecule.

Everything that separates them is regulatory and practical. Regulators approve indications — specific uses in specific populations — not chemicals. Ozempic was approved first, in December 2017, as a type 2 diabetes drug, and its label later grew to cover cardiovascular risk reduction and kidney protection in people with diabetes. Wegovy was approved in June 2021 as a chronic weight-management drug, with its own trial program, its own pen, its own dose markings, and its own maximum strength of 2.4 mg — above Ozempic's 2 mg ceiling. That 0.4 mg gap sounds trivial and is not: the weight-loss trials that made semaglutide a household word were run at 2.4 mg.

So when people ask whether Ozempic and Wegovy are "the same," the honest answer is: same active ingredient, different product. The rest of this page is about why that distinction has real consequences for what each drug is proven to do, what it costs, and who can get it.

Same molecule: how semaglutide works

Semaglutide is a modified copy of human glucagon-like peptide-1 (GLP-1), an incretin hormone released by intestinal L-cells after a meal. Native GLP-1 is destroyed within minutes; semaglutide's engineered backbone and attached fatty-acid chain let it bind albumin in the blood and survive for roughly a week, which is why one injection covers seven days. Both Ozempic and Wegovy rely on that same half-life.

The hormone does several things at once, mapped out in detail in the physiology literature on glucagon-like peptide 1. It amplifies insulin release from the pancreas, but only when blood glucose is elevated — which is why GLP-1 drugs rarely cause hypoglycemia on their own. It suppresses glucagon, slows how quickly the stomach empties, and acts on appetite centers in the brainstem and hypothalamus that register fullness. The glucose-lowering effect drives the diabetes benefit; the appetite and gastric effects drive the weight loss. Because it is one molecule doing all of this, the split between "diabetes drug" and "weight drug" is a matter of dose and marketing, not biology. Our primer on the wider GLP-1 agonist class covers how the different molecules in this family diverge.

The trials behind each brand: SUSTAIN vs STEP

The clearest way to see the Ozempic–Wegovy split is through the two trial programs that built each label. They tested the same molecule but asked different questions.

Ozempic rests on the SUSTAIN program. The head-to-head SUSTAIN 7 trial randomized 1,201 people with type 2 diabetes to semaglutide or dulaglutide for 40 weeks; semaglutide 1 mg lowered HbA1c by 1.8 percentage points against 1.4 for dulaglutide, and cut body weight by 6.5 kg against 3.0 kg. SUSTAIN FORTE compared semaglutide 2 mg with 1 mg in poorly controlled diabetes and reported HbA1c drops of 2.2 versus 1.9 points and weight loss of 6.9 versus 6.0 kg. The heart evidence came from SUSTAIN-6, where the composite of cardiovascular death, non-fatal heart attack and non-fatal stroke occurred in 6.6% on semaglutide versus 8.9% on placebo, a 26% relative reduction. The FLOW trial then reduced major kidney events by 24% in diabetes with chronic kidney disease, producing the 2025 label expansion. Notice what these trials measured: blood sugar, hearts, kidneys — not pounds as a primary endpoint.

Wegovy rests on the STEP program. The headline trial, STEP 1, randomized 1,961 adults with obesity or overweight and no diabetes to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% versus −2.4%, and about half the treatment group lost at least 15% of body weight. STEP 2 tested the same dose in people who also had type 2 diabetes and reported a smaller −9.6% versus −3.4% — a reminder that people with diabetes reliably lose less on this class. STEP 4 showed the drug behaves like maintenance therapy: after everyone reached 2.4 mg, continuing produced 7.9% further loss while switching to placebo produced 6.9% regain. And the SELECT trial gave semaglutide 2.4 mg to 17,604 adults with cardiovascular disease and no diabetes and found a 20% reduction in major cardiovascular events, which added a heart indication to Wegovy in 2024. A separate program, ESSENCE, later tested semaglutide 2.4 mg in metabolic dysfunction-associated steatohepatitis, with 62.9% achieving resolution of steatohepatitis versus 34.3% on placebo.

Ozempic vs Wegovy side by side

The table lines up the two products across the dimensions people actually compare. Strengths shown are label maximums, listed for identification only — this is not dosing guidance.

Is Ozempic FDA approved for weight loss?

No — and this is the single most consequential fact in the comparison. Ozempic has never been approved as a weight-loss drug. Its approvals cover glycemic control in type 2 diabetes, reduction of major cardiovascular events in diabetes with established heart disease, and slowing chronic kidney disease in diabetes. Weight loss is conspicuously absent from that list.

That does not stop it being used for weight. Prescribing an approved drug for an unapproved purpose is called off-label prescribing, and it is legal and routine in medicine, governed by clinical judgment rather than the FDA label. During the years when Wegovy was in short supply, a large amount of semaglutide-for-weight demand was met by off-label Ozempic prescriptions instead. The catch is that off-label use sits outside the studied indication: the weight-loss evidence base was built on Wegovy's 2.4 mg dose, and Ozempic's ceiling is lower, so an off-label Ozempic user may never reach the dose the obesity trials actually tested. Wegovy, by contrast, is the semaglutide brand that carries the weight-management approval, from the FDA all the way through to how it is marketed.

Which is better for weight loss?

There is no head-to-head trial of Ozempic against Wegovy, and there never will be, because it would be a trial of a drug against itself at different doses. What the evidence supports is straightforward: at equal milligram doses, they are the same molecule and would be expected to produce the same effect. The reason Wegovy is "better" for weight loss is that it is licensed to go higher — to 2.4 mg — and higher semaglutide doses produce more weight loss, up to a point.

The numbers frame it. At Ozempic's diabetes strengths, semaglutide produced roughly 6 to 7 kg of weight loss over 40 weeks. At Wegovy's 2.4 mg, STEP 1 produced 14.9% of body weight over 68 weeks — for many participants, two to three times as much. For context, the previous best-in-class weight drug, liraglutide 3.0 mg, produced roughly 8% in its pivotal trial (PubMed 26132939). Semaglutide's position at the top of the mono-agonist GLP-1 class is confirmed by systematic reviews of head-to-head GLP-1 studies.

What can beat Wegovy is a different molecule. In SURMOUNT-5, the dual GIP/GLP-1 agonist tirzepatide produced 20.2% weight loss against 13.7% for semaglutide 2.4 mg over 72 weeks. That is a comparison of two different drugs, covered in our breakdowns of tirzepatide vs semaglutide and Mounjaro vs Ozempic. Within the Ozempic-versus-Wegovy question specifically, the deciding variable is dose and indication, not chemistry.

Ozempic vs Wegovy side effects

Because they are the same molecule, they share a side-effect fingerprint. The dominant category for both is gastrointestinal: nausea, diarrhea, vomiting, constipation and abdominal pain lead the adverse-event tables in every semaglutide trial, appear mostly during dose escalation, and are the leading reason people stop. In SUSTAIN 7, gastrointestinal disorders affected 43 to 44% of semaglutide participants; across the STEP weight-loss trials, roughly three-quarters to four-fifths of participants reported at least one GI event.

The one systematic difference is intensity, and it follows the dose. Wegovy's 2.4 mg produces more frequent and, for some, more severe GI effects than Ozempic's lower diabetes doses, simply because the dose is higher. Discontinuation for adverse events ran around 7% in STEP 1. Beyond the gut, both labels carry the identical set of warnings — acute pancreatitis, gallbladder disease, acute kidney injury from dehydration during vomiting, hypoglycemia when combined with insulin or sulfonylureas, diabetic retinopathy complications, and a boxed warning about thyroid C-cell tumors seen in rodents, with the same contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN2. Both also cause a meaningful fraction of lost weight to come from lean tissue, which is why trial protocols paired them with diet and activity counseling.

Insurance and cost: why coverage differs

This is where two products containing the same drug diverge most sharply. US list price for Ozempic has sat around $935 to $970 a month; Wegovy has run higher, roughly $1,300 to $1,350. But list price is almost fictional — what a person actually pays depends on coverage, and coverage depends on the indication written on the prescription.

The pattern is consistent and frustrating: many commercial plans pay for Ozempic because type 2 diabetes is a condition insurers reliably cover, while excluding Wegovy because weight management sits in a separate formulary bucket that many plans limit or deny. US Medicare has historically been prohibited from covering drugs prescribed solely for weight loss, though coverage exists when a cardiovascular indication applies. That coverage gap is the practical engine behind off-label Ozempic prescribing — it is often the cheaper, more reimbursable route to the same molecule. On the cash side, Novo Nordisk has sold semaglutide directly to self-paying patients through its NovoCare Pharmacy channel at a few hundred dollars a month, and savings cards can lower commercially insured copays further. Prices, savings terms and Medicare rules change frequently, so treat every figure here as a snapshot and verify current pricing directly.

Shortages, compounded semaglutide, and the gray market

Both brands spent much of 2022 through 2024 on the FDA drug shortage list as demand outran supply. That listing temporarily allowed US compounding pharmacies to prepare semaglutide, and a large telehealth market grew around cheaper compounded versions. When the FDA declared the semaglutide shortage resolved in early 2025, the legal basis for routine mass compounding narrowed sharply, and much of that supply was supposed to wind down.

Compounded semaglutide is not the same product as Ozempic or Wegovy. A 2026 analysis in Annals of Pharmacotherapy examining compounded semaglutide and tirzepatide products found they frequently use unique formulations and salt forms whose efficacy and safety data are largely unknown. Separately, the FDA has warned about dosing errors from users drawing doses out of multi-dose vials, and about counterfeit pens entering the supply chain. Anything sold online as "research-grade" semaglutide is outside the pharmacy system entirely, with no verified identity, sterility or strength — see are peptides legal for how that category actually works. Whichever brand a clinician prescribes, semaglutide behaves like treatment for a chronic condition: when it was withdrawn in the STEP 1 extension, participants regained about two-thirds of the weight they had lost and their cardiometabolic gains reversed with it (PubMed 35441470). That is a strong argument for keeping a clean record of what actually happens week to week.

Frequently asked questions

Sources

Every claim above traces to peer-reviewed literature indexed on PubMed:

1. The physiology of glucagon-like peptide 1 — PubMed 17928588
2. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial — PubMed 29397376
3. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE) — PubMed 34293304
4. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) — PubMed 27633186
5. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) — PubMed 38785209
6. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — PubMed 33567185
7. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2) — PubMed 33667417
8. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: The STEP 4 Randomized Clinical Trial — PubMed 33755728
9. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — PubMed 37952131
10. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE) — PubMed 40305708
11. GLP-1 receptor agonists: an updated review of head-to-head clinical studies — PubMed 33767808
12. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management — PubMed 26132939
13. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) — PubMed 40353578
14. Weight regain and cardiometabolic effects after withdrawal of semaglutide — PubMed 35441470
15. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown — PubMed 41689811

Approval dates, label indications and pricing reflect FDA prescribing information and Novo Nordisk announcements. Prices and coverage rules change frequently — verify current figures directly.

Keep reading